SAPHNELO (anifrolumab-fnia)
IMMUNOSUPPRESSIVE - INTERFERON INHIBITOR, MONOCLONAL AB · SYSTEMIC LUPUS ERYTHEMATOSUS
AstraZeneca Pharmaceuticals
Drug class
Immunosuppressive - Interferon Inhibitor, Monoclonal Ab
The drug class "Immunosuppressive - Interferon Inhibitor, Monoclonal Ab" represents targeted biologic agents designed to attenuate pathologic immune responses by interfering with interferon cytokine signaling. Read more about Immunosuppressive - Interferon Inhibitor, Monoclonal Ab
3 drugs in this class 2 manufacturers
Drugs in Immunosuppressive - Interferon Inhibitor, Monoclonal Ab
GAMIFANT (emapalumab-lzsg)
IMMUNOSUPPRESSIVE - INTERFERON INHIBITOR, MONOCLONAL AB · MACROPHAGE ACTIVATION SYNDROME ·+1
BIOVITRUM
SAPHNELO PEN (anifrolumab-fnia)
IMMUNOSUPPRESSIVE - INTERFERON INHIBITOR, MONOCLONAL AB · SYSTEMIC LUPUS ERYTHEMATOSUS
AstraZeneca Pharmaceuticals
Filter & compare in the drug finder →
Opens the drug finder with Immunosuppressive - Interferon Inhibitor, Monoclonal Ab preselected. Add indication or manufacturer filters there.
The drug class "Immunosuppressive - Interferon Inhibitor, Monoclonal Ab" represents targeted biologic agents designed to attenuate pathologic immune responses by interfering with interferon cytokine signaling.
The principal mechanism involves binding to specific cytokine pathways, such as blocking the type I interferon receptor subunit 1, which inhibits the downstream gene expression and inflammatory cascade driven by interferons like IFN-alpha and IFN-beta.
This class is primarily utilized as an add-on immunosuppressive therapy for moderate to severe systemic autoimmune conditions, most notably active systemic lupus erythematosus.
-
nih.gov
The drug class "Immunosuppressive - Interferon Inhibitor, Monoclonal Ab" represents targeted biologic agents designed to attenuate pathologic immune responses by interfering with interferon cytokine signaling This class is primarily utilized as an add-on immunosuppressive therapy for moderate to severe systemic autoimmune conditions, most notably active systemic lupus erythematosus
-
astrazeneca.com
The drug class "Immunosuppressive - Interferon Inhibitor, Monoclonal Ab" represents targeted biologic agents designed to attenuate pathologic immune responses by interfering with interferon cytokine signaling The principal mechanism involves binding to specific cytokine pathways, such as blocking the type I interferon receptor subunit 1, which inhibits the downstream gene expression and inflammatory cascade driven by interferons like IFN-alpha and IFN-beta This class is primarily utilized as an ...
-
nih.gov
The principal mechanism involves binding to specific cytokine pathways, such as blocking the type I interferon receptor subunit 1, which inhibits the downstream gene expression and inflammatory cascade driven by interferons like IFN-alpha and IFN-beta
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.